21 November 2025 in Cancer Research
Supraphysiologic androgen (SPA) treatment can paradoxically restrict the growth of castration-resistant prostate cancer (CRPC) with high androgen receptor (AR) activity, which is the basis for the use of bipolar androgen therapy (BAT) for patients with this disease. Although androgens are widely appreciated for enhancing anabolic metabolism, how SPA-mediated metabolic changes alter prostate cancer progression and therapy response is unknown. In this study, we report that SPA markedly increased intracellular and secreted polyamines in prostate cancer models. AR binding at enhancer sites upstream of the ornithine decarboxylase 1 (ODC1) promoter increased the abundance of ODC, a rate-limiting enzyme of polyamine synthesis, and de novo synthesis of polyamines from arginine. SPA-stimulated polyamines enhanced prostate cancer fitness, as dCas9-KRAB–mediated inhibition of AR regulation of ODC1 or direct ODC inhibition by difluoromethylornithine (DFMO) increased the efficacy of SPA. Mechanistically, AR activation combined with the loss of negative feedback by polyamines increased the activity of S-adenosylmethionine decarboxylase 1, leading to the depletion of its substrate, S-adenosylmethionine, and global protein methylation. These data provided the rationale for a clinical trial testing the safety and efficacy of BAT in combination with DFMO for patients with metastatic CRPC. Pharmacodynamic studies of this therapeutic combination in the first five patients in the trial indicated that this approach effectively depleted polyamines in plasma. Thus, the AR potently stimulates polyamine synthesis, which constitutes a vulnerability in prostate cancer treated with SPA that can be targeted therapeutically. Significance: Increased polyamine synthesis is a prominent metabolic change induced by the androgen receptor that drives tumor progression and confers a targetable vulnerability in advanced prostate cancer. See related commentary by Alizadeh-Ghodsi and Goldstein, p. 1095
8 April 2026 in The Prostate
Background: Prostate cancer can be an indolent disease with which patients can live for many years. Thus, an understanding of how therapy and its ensuing resistance affect prostate cancer kinetics may guide efforts to determine optimal timing of therapy initiation. Despite the fact that castration has been used as therapy for prostate cancer for more than 70 years, no prior study has systematically quantified the effect of castration resistance on the rate of progression. The prostate‐specific antigen doubling time (PSADT) estimates prostate cancer kinetics and predicts overall survival, but whether PSADT changes as a result of castration resistance is not known. Methods: Here, we studied the longitudinal change in the PSADT before castration and following the development of castration resistance in a cohort of 40 patients with prostate cancer. Results: The PSADT of castration‐resistant prostate cancer (CR‐PSADT) was markedly shorter than the matched PSADT of castration‐naïve prostate cancer (CN‐PSADT) (median 2.6 months vs. 5.8 months, p < 0.001). The CR‐PSADT positively correlated with the CN‐PSADT and with overall survival. Sensitivity analysis suggested that the PSADT did not change as a function of time during progression when treatment was unchanged. Using a separate cohort of 36 patients with metastatic CRPC, we confirmed a positive correlation of CR‐PSADT with overall survival and identified a negative correlation with the Ki‐67 proliferation index of metastatic tumor biopsies. Conclusions: Castration‐resistant prostate cancer is associated with markedly accelerated disease kinetics compared with castration‐naïve prostate cancer. This acceleration of disease progression has the potential to shorten the survival of some patients with indolent disease who are treated prematurely with ADT.